Recent studies have shown that mutations in KRAS, SKT11, KEAP1, JAK1/2, B2M, APC, MTOR and TP53 and co-mutations of these genes are the main determinants of ICB response in non-small-cell lung cancer (NSCLC) patients, influencing metabolic changes in cancer cells, cytotoxic T cells, and the efficacy of ICIs [26,27]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.